Editor’s note: Originally published on Oct. 12, 2023. Updated Feb. 28, 2024, to add fact sheets. According to the Agency for Healthcare Research and Quality (AHRQ), a leading cause of medical errors and poor care is a lack of communication between healthcare providers.1 As healthcare has evolved, the importance of holistic care has become more…
Search results for: fatigue
Neuropsychiatric Lupus Research Benefits from Functional MRI & Insights into Microglia
Experts described the latest breakthroughs related to lupus and the brain, including the use of functional magnetic resonance imaging (fMRI) to gain insights into brain fog. Research into the role of microglia in neuropsychiatric lupus is also described.
Crucial to Rheumatic Care: Insights into the Importance of Trust
Gaining trust has a significant effect on disease management and patient care, according to experts at ACR Convergence 2023. Here are insights into the barriers to that trust and how healthcare providers can develop trusting relationships with their patients.
A World View: The ACR Global Research Exchange Program Promotes Mentorship & Long-Term Collaboration in Rheumatology
2023 marks the post-pandemic return of research exchanges hosted by the ACR & EULAR to benefit junior academic rheumatologists & rheumatology professionals.
Beyond the Rheumatologist: Interprofessional Alliances Are Crucial to Rheumatic Care
How can we ensure patients are receiving care that addresses all of the ways rheumatic disease affects their life? In this ACR Convergence 2023 session, experts discuss the value of a strong interprofessional care team.
Duke University Names Dr. Megan Clowse to Lead Rheumatology Division
In October 2023, Megan E.B. Clowse, MD, MPH, a renowned expert in the field of rheumatology and immunology, was named the new chief of the Division of Rheumatology and Immunology at Duke University School of Medicine, Durham, N.C. Dr. Clowse, who serves as an associate professor of medicine in Duke’s Division of Rheumatology and Immunology…
3 AC&R Study Summaries: Prescribing Patterns, PMR & Glucocorticoids, & Infection Screening
A Shift in Prescribing Patterns Safety issues prompt discontinuation of tofacitinib By Stephanie Song, MD, & Joshua F. Baker, MD, MSCE Why was this study done? The ORAL Surveillance study highlighted risks of cardiac events, thromboembolism (VTE) and malignancy associated with use of Janus kinase inhibitors (JAKi). We sought to determine the impact of safety…
Lifestyle Medicine Interventions Can Benefit Patients with Rheumatic Disease
Lifestyle medicine interventions, such as dietary changes, movement and mindfulness, in combination with conventional treatment, may help alleviate symptoms of rheumatic disease, according to panelists at ACR Convergence 2023.
FDA Approves Sarilumab for Adults with Glucocorticoid-Resistant Polymyalgia Rheumatica
On Feb. 28, 2023, the U.S. Food & Drug Administration (FDA) approved sarilumab (Kevzara) for the treatment of adults with polymyalgia rheumatica (PMR) for whom glucocorticoids have proved inadequate or who cannot tolerate a glucocorticoid taper.1,2 Sarilumab is an interleukin (IL) 6 receptor antagonist. In May 2017, the FDA initially approved the agent for the…
How to Treat Refractory Polymyalgia Rheumatica
Patients with polymyalgia rheumatica (PMR) who had relapsed while tapering glucocorticoid therapy were more likely to achieve sustained remission at one year and have a lower glucocorticoid exposure if they were treated with sarilumab (Kevzara) plus a rapid, 14-week glucocorticoid taper than if they received placebo plus a standard, 52-week glucocorticoid taper. This is according…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 58
- Next Page »